Stay updated on Autologous TILs in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Autologous TILs in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Autologous TILs in Solid Tumors Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-06T17:23:05.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    0.7%
    Check dated 2025-05-30T13:08:19.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-23T10:29:05.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-05-01T23:21:03.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The webpage has been updated to include new drug information related to metastatic melanoma and other cancers, while significant details about a previous study on adoptive cell therapy have been removed.
    Difference
    23%
    Check dated 2025-04-17T07:51:54.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new Phase 2 study evaluating adoptive cell therapy (ACT) with TIL (LN-144/LN-145) in combination with immune checkpoint inhibitors for various cancers, including melanoma and non-small cell lung cancer. Key details about patient eligibility, treatment regimens, and study objectives have been added, enhancing the clarity and comprehensiveness of the study information.
    Difference
    28%
    Check dated 2025-04-10T05:11:37.000Z thumbnail image

Stay in the know with updates to Autologous TILs in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Autologous TILs in Solid Tumors Clinical Trial page.